The startup develops clinically validated virtual reality therapeutic devices that provide on-demand, all-in-one platforms for managing acute and chronic pain. These devices enhance clinical outcomes for patients with serious health conditions by offering targeted pain relief solutions.

Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.

GroundGame Health utilizes a HITRUST-certified platform to connect economically disadvantaged populations with primary care and community resources, addressing gaps in social determinants of health. By facilitating direct referrals and person-to-person engagement, the platform improves health outcomes and reduces costs for health plans and providers.

HiberCell is developing therapeutic agents that target adaptive stress mechanisms in cancer cells, specifically through the inhibition of stress-mitigating pathways and the activation of stress signaling pathways. This approach aims to address treatment resistance, cancer relapse, and metastasis, ultimately enabling patients to achieve longer, cancer-free lives.

Paradigm is developing a platform that integrates clinical trial management systems to enhance trial efficiency and reduce participation barriers for both patients and healthcare providers. By creating a unified infrastructure, Paradigm aims to provide equitable access to clinical trials, accelerating the delivery of potentially life-saving therapies.

Relation Therapeutics utilizes single-cell multi-omics, functional assays, and machine learning to identify druggable targets and develop therapies for severe diseases, starting with osteoporosis. By integrating high-resolution biological data directly from patient tissue, the company aims to enhance understanding of disease mechanisms and improve treatment outcomes.

Resilience is a biomanufacturing company that utilizes advanced technologies to produce complex medicines, including cell and gene therapies, while ensuring the integrity of biopharmaceutical supply chains. The company addresses the challenge of scaling production to meet the growing demand for innovative therapies by providing tailored, end-to-end manufacturing solutions.

Stipple Bio provides a high‑resolution epitope‑level discovery platform that maps thousands of molecular points on tumor and normal cells to identify tumor‑specific epitopes invisible to conventional antibody discovery. By delivering ultra‑fine epitope maps and comparative analytics, the company enables pharma, biotech, and academic researchers to design more selective oncology antibodies and biologics, expanding target space and accelerating candidate development.

This startup offers next-day plasmid sequencing services with integrated bioinformatics analysis, enabling faster and more cost-effective bioscience research. Their machine learning-driven platform provides high-throughput sequencing and robust data analysis for researchers.

Transition Bio operates an end‑to‑end condensate drug discovery platform that integrates droplet microfluidics with advanced cellular imaging. The platform generates molecular‑level data on how chemical compounds affect condensate systems, enabling precise assessment of drug candidates. Machine learning and AI are applied to optimize chemical matter and accelerate novel therapeutic development.

Triveni Bio utilizes a genetics-informed precision medicine platform to develop functional antibodies targeting immunological and inflammatory disorders. The company focuses on identifying and validating therapeutic targets with strong genetic rationale, aiming to improve treatment options for diseases with limited existing therapies.

Weave Bio provides an AI-native regulatory platform designed to streamline the preparation and management of complex therapeutic dossiers. The platform accelerates data organization, authoring, review, and publishing using eCTD-formatted templates, enabling faster and more accurate submissions. It facilitates real-time team collaboration and content generation, allowing regulatory professionals to direct strategy rather than manually compile documentation.